Relapsing-remitting Multiple Sclerosis (RRMS) Clinical Trial
Official title:
Observational, Multicenter Study to Describe the Persistence in Relapsing Remitting Multiple Sclerosis Naive Patients With Low-moderate Activity Treated With Ozanimod (Zeposia®) in Clinical Practice in Spain
The purpose of the study is to collect clinical data on the persistence with ozanimod treatment, as well as to describe its effects on participant-relevant outcome parameters in treatment-naïve participants with RRMS.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05177523 -
Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
|
||
| Withdrawn |
NCT05172466 -
Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab
|
N/A | |
| Recruiting |
NCT05304520 -
A Study for Tysabri Participant Preference
|
||
| Completed |
NCT04115488 -
Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®
|
Phase 3 | |
| Active, not recruiting |
NCT03846219 -
MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
|
Phase 2 | |
| Completed |
NCT02587065 -
Plegridy Satisfaction Study in Participants
|
Phase 4 | |
| Not yet recruiting |
NCT02568111 -
Brimonidine Tartrate for the Treatment of Injection Related Erythema
|
Phase 4 | |
| Terminated |
NCT01633112 -
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
|
Phase 3 | |
| Completed |
NCT01738347 -
Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).
|
Phase 1 | |
| Terminated |
NCT02881567 -
Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
|
Phase 3 | |
| Not yet recruiting |
NCT05245344 -
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study
|